H. Pandha

714 total citations
26 papers, 548 citations indexed

About

H. Pandha is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, H. Pandha has authored 26 papers receiving a total of 548 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in H. Pandha's work include Virus-based gene therapy research (11 papers), Cancer Research and Treatments (9 papers) and Immunotherapy and Immune Responses (5 papers). H. Pandha is often cited by papers focused on Virus-based gene therapy research (11 papers), Cancer Research and Treatments (9 papers) and Immunotherapy and Immune Responses (5 papers). H. Pandha collaborates with scholars based in United Kingdom and United States. H. Pandha's co-authors include Kevin J. Harrington, Richard G. Vile, Alan Melcher, John Chester, Karol Sikora, David Stirling, Steve Nicholson, J. Blake Bartlett, Angus Dalgleish and Hartmut Kristeleit and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Oncogene.

In The Last Decade

H. Pandha

25 papers receiving 531 citations

Peers

Countries citing papers authored by H. Pandha

Since Specialization

Citations

This map shows the geographic impact of H. Pandha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Pandha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Pandha more than expected).

Fields of papers citing papers by H. Pandha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Pandha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Pandha. The network helps show where H. Pandha may publish in the future.

Co-authorship network of co-authors of H. Pandha

This figure shows the co-authorship network connecting the top 25 collaborators of H. Pandha. A scholar is included among the top collaborators of H. Pandha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Pandha. H. Pandha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy 2016 ·Gene Therapy ·Elizabeth J. Ilett, Tim Kottke, Jill Thompson, Karishma Rajani, S. Zaidi, Laura Evgin, Matt Coffey, Christy Ralph, (unknown), H. Pandha, Kevin J. Harrington, Peter J. Selby, Richard J. Bram, Alan Melcher, Richard G. Vile	59
2	438 Engrailed 2 protein (EN2) as a novel biomarker in epithelial ovarian cancer 2015 ·European Journal of Cancer ·(unknown), (unknown), N. E. Annels, M. Denyer, (unknown), H. Pandha	1
3	Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in V600D/EBRAF mutant melanoma depends on JNK and TNF-α signaling 2013 ·Oncogene ·Joan Kyula, Aadil Khan, David Mansfield, Eleni Karapanagiotou, Martin McLaughlin, Victoria Roulstone, S. Zaidi, (unknown), Yann Touchefeu, R. Seth, Nanhai G. Chen, Yong Yu, (unknown), Alan Melcher, Richard G. Vile, H. Pandha, M. Ajaz, Aladar A. Szalay, Kevin J. Harrington	33
4	EN2: A candidate antigen for the development of targeted therapies in ovarian cancer. 2011 ·Journal of Clinical Oncology ·Agnieszka Michael, Catherine Riley, Shadi Bokaee, M. Denyer, H. Pandha, Nicola Annels	2
5	Use of gemcitabine- (Gem) and fluropyrimidine (FP)-based chemotherapy to reduce myeloid-derived suppressor cells (MDSCs) in pancreatic (PC) and esophagogastric cancer (EGC). 2011 ·Journal of Clinical Oncology ·(unknown), N. E. Annels, (unknown), H. Pandha, Gary Middleton	11
6	A phase I/II study of oncolytic reovirus plus carboplatin/paclitaxel in patients with advanced solid cancers with emphasis on squamous cell carcinoma of the head and neck (SCCHN). 2010 ·Journal of Clinical Oncology ·(unknown), (unknown), H. Pandha, (unknown), (unknown), K.L. Mettinger, Kevin J. Harrington	5
7	Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics 2010 ·Cytokine & Growth Factor Reviews ·Kevin J. Harrington, Richard G. Vile, Alan Melcher, John Chester, H. Pandha	76
8	A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN (R)) in combination with radiation in patients with advanced malignancies. 2007 ·Molecular Cancer Therapeutics ·(unknown), Laura Vidal, Alan Melcher, Kate Newbold, (unknown), (unknown), Rajiv Agarwal, Christine White, Katie Twigger, Matt Coffey, K.L. Mettinger, Bruce Thompson, H. Pandha, Johann S. de Bono, Kevin J. Harrington	5
9	Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo 2007 ·Gene Therapy ·Christine L. White, (unknown), Katie Twigger, Peter F. Searle, Shreerang Bhide, Richard G. Vile, Alan Melcher, H. Pandha, Kevin J. Harrington	15
10	Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy 2006 ·Prostate Cancer and Prostatic Diseases ·(unknown), B Meyer, Michael Bailey, H. Pandha	6
11	348 POSTER A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer 2006 ·European Journal of Cancer Supplements ·Tami Yap, (unknown), H. Pandha, James Spicer, Laurence Digue, Matt Coffey, Bruce Thompson, S.B. Kaye, Kevin J. Harrington, Johann S. de Bono	2
12	Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer 2005 ·Prostate Cancer and Prostatic Diseases ·James Spicer, T.A. Plunkett, Navita Somaiah, Stephen L. Chan, Anne Kendall, (unknown), H. Pandha	11
13	Results of a phase I/II clinical trial with OncoVEX^GM-CSF, a second generation oncolytic herpes simplex virus 2005 ·Journal of Clinical Oncology ·R. S. Coffin, (unknown), (unknown), Nicholas D. James, Colin Love, Agnieszka Michael, H. Pandha, J. A. Steiner, Neil Steven, R. Charles Coombes	4
14	Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers 2004 ·British Journal of Cancer ·J. Blake Bartlett, (unknown), Ian Clarke, Keith Dredge, Steve Nicholson, Hartmut Kristeleit, (unknown), H. Pandha, George W. Muller, David Stirling, Jerome B. Zeldis, Angus Dalgleish	123
15	PC-SPES: phytotherapy for prostate cancer 2002 ·The Lancet ·H. Pandha, (unknown)	12
16	The role of autologous transplantation in patients with multiple myeloma aged 65 years and over 2000 ·Bone Marrow Transplantation ·Bhawna Sirohi, R Powles, J Treleaven, Paul N. Mainwaring, S Kulkarni, H. Pandha, Niyati Bhagwati, C Horton, Seema Singhal, Jayesh Mehta	86
17	Metastatic Extramedullary Plasmacytoma of the Lung 1999 ·Leukemia & lymphoma ·(unknown), H. Pandha, J. Treleaven, R Powles	13
18	Gene therapy for prostate cancer 1997 ·British Journal of Urology ·Karol Sikora, H. Pandha	25
19	Genetic prodrug activation therapy 1997 ·The Lancet ·Lisa Martin, Richard G. Vile, NR Lemoine, Karol Sikora, H. Pandha	6
20	Gene therapy in gastroenterology. 1996 ·Gut ·H. Pandha, N R Lemoine	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact